Skip to content

Abstract 8341: High-Sensitivity C-Reactive Protein, All-Cause Mortality and Heart Failure Hospitalization After Acute Coronary Syndrome in Type 2 Diabetes: Insights from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) Trial

Nov 2026 · Circulation · 0 citations

Abstract

Background: Patients with type 2 diabetes (T2D) remain at high risk for adverse outcomes after acute coronary syndrome (ACS). High-sensitivity C-reactive protein (hsCRP) may identify residual risk in this setting. Objective: To evaluate whether baseline hsCRP is associated with all-cause mortality (ACM) and heart failure hospitalization (HFH) after ACS in patients with T2D, and whether the association with HFH persists after adjustment for cardiac biomarkers. Methods: We performed a post hoc analysis of 5,380 patients with T2D and recent ACS in the EXAMINE trial who had available baseline hsCRP. Patients were categorized into hsCRP tertiles: T1 ≤1.30, T2 1.30-3.70, and T3 >3.70 mg/L. Cox proportional hazards models evaluated ACM, and Fine-Gray models evaluated HFH, treating death without prior HFH as a competing event. Models were adjusted for age, sex, BMI, HbA1c, systolic blood pressure, prior HFH, T2D duration, history of myocardial infarction, hypertension, smoking and estimated glomerular filtration rate. Cumulative incidence curves were compared. In sequential biomarker-adjusted analyses, associations between log-hsCRP as continuous predictor and HFH were examined at 1 year and over full follow-up, with additional adjustment for troponin I (TnI) and clinical B-type natriuretic peptide (BNP). Sensitivity analyses using Olink BNP were performed. Results: Across increasing hsCRP tertiles, patients had higher BMI, HbA1c, smoking prevalence, prior HFH, TnI, BNP, and more frequent insulin and diuretic use. Compared with T1, after multivariable adjustment, T3 was associated with higher risk of ACM (HR 1.77, 95% CI 1.35-2.33; P<0.001) and HFH (SHR 1.69, 95% CI 1.19-2.40; P=0.0034), whereas T2 was not. T3 had the highest cumulative incidence of ACM and HFH (log-rank p<0.001 and Gray's test p<0.001, respectively) (Fig 1) . Log-hsCRP remained associated with 1-year HFH after adjustment for TnI (HR 1.26, 95% CI 1.10-1.44; P<0.001), clinical BNP (HR 1.39, 95% CI 1.06-1.81; P=0.0160), and both biomarkers (HR 1.33, 95% CI 1.00-1.77; P=0.049). Findings were consistent in the Olink BNP sensitivity analyses after adjustment for Olink BNP alone (HR 1.27, 95% CI 1.11-1.45; P<0.001) and Olink BNP plus TnI (HR 1.23, 95% CI 1.07-1.41; P=0.0039). Over full follow-up, the association was preserved after adjustment for TnI alone (HR 1.20, 95% CI 1.06-1.35; P=0.0034), Olink BNP alone (HR 1.20, 95% CI 1.06-1.35; P=0.0032), and Olink BNP plus TnI (HR 1.16, 95% CI 1.03-1.32; P=0.014), but was attenuated in the smaller subset of patients with available clinical BNP. (Fig 2) . Conclusion: In patients with T2D after recent ACS, elevated hsCRP identified a high-risk phenotype associated with ACM and HFH. Persistence of the association between hsCRP and HFH after adjustment for TnI and BNP suggests that inflammation captures residual HF risk not fully explained by myocardial injury or cardiac stress biomarkers.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.